GLP-1 medications are transitioning from groundbreaking treatments to widely used solutions, and the scope of this shift is becoming increasingly evident. These drugs can reduce calorie intake by 15–35%, result in fewer sick days, have millions of active users, and are prompting the development of hundreds of new drugs. They are potentially transforming not only healthcare but also the global economy.

Join the Healthcare Business Network for a lively fireside chat with Henry Dimbleby, co-founder of Leon, author of the UK National Food Strategy, and Managing Partner at Bramble Partners. In this forward-looking discussion, Henry will consider whether GLP-1 drugs are a medical breakthrough or the start of a fundamental overhaul of the modern food system. The conversation will cover the impacts on managing chronic diseases, insurance models, supply chains in the agrifood sector, demand for ultra-processed foods, workforce efficiency, and emerging research on brain reward, addiction, and behavioral health. With obesity costing the UK economy £126 billion annually and treatment costs likely to decrease significantly as new oral therapies become available, the effects will extend well beyond healthcare. This session offers YPOErs a unique, cross-sector view on a major health and economic transformation of this decade.

Key insights from this session include:

Understanding patent cycles, pricing trends, and regulatory changes.
Business and investment consequences of large-scale metabolic shifts.
How GLP-1 adoption might influence food production, insurance, and productivity.
The impact of these therapies on addiction, appetite regulation, and mental health.

Discover the shift that could redefine health, food, and productivity.